MedPath
HSA Approval

BORACTIB POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL

SIN15243P

BORACTIB POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL

BORACTIB POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL

May 26, 2017

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS, SUBCUTANEOUS

Medical Information

L01XX32

xl 01 xx 32

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

S.C. SINDAN-PHARMA S.R.L.

Active Ingredients

Bortezomib

3.5 mg/vial

Bortezomib

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BORACTIB POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL - HSA Approval | MedPath